Blair William & CO Krystal Biotech, Inc. Transaction History

Blair William & CO

$33.5 Billion
Q4 2024

A detailed history of Blair William & CO transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Blair William & CO holds 7,443 shares of KRYS stock, worth $1.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,443

Previous 5,568 33.67%

Holding current value

$1.14 Million

Previous $1.01 Million 15.22%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$156.64 - $199.61 $293,700 - $374,268	1,875 Added 33.67%	7,443 $1.17 Million
Q3 2024 Nov 12, 2024	BUY	$174.7 - $213.66 $349 - $427	2 Added 0.04%	5,568 $1.01 Million
Q2 2024 Aug 12, 2024	SELL	$153.12 - $183.64 $5,512 - $6,611	-36 Reduced 0.64%	5,566 $1.02 Million
Q1 2024 May 09, 2024	SELL	$108.01 - $179.35 $59,405 - $98,642	-550 Reduced 8.94%	5,602 $996,000
Q4 2023 Feb 12, 2024	BUY	$96.0 - $128.29 $1,920 - $2,565	20 Added 0.33%	6,152 $763,000
Q3 2023 Nov 09, 2023	SELL	$108.51 - $130.22 $96,031 - $115,244	-885 Reduced 12.61%	6,132 $711,000
Q2 2023 Aug 11, 2023	SELL	$78.48 - $130.32 $3,139 - $5,212	-40 Reduced 0.57%	7,017 $823,000
Q1 2023 May 12, 2023	BUY	$72.39 - $84.27 $7,239 - $8,427	100 Added 1.44%	7,057 $564,000
Q4 2022 Feb 10, 2023	BUY	$63.14 - $79.9 $36,621 - $46,342	580 Added 9.1%	6,957 $551,000
Q3 2022 Nov 09, 2022	BUY	$64.85 - $82.4 $83,332 - $105,884	1,285 Added 25.24%	6,377 $444,000
Q2 2022 Aug 10, 2022	BUY	$48.93 - $73.47 $249,151 - $374,109	5,092 New	5,092 $334,000
Q1 2022 May 13, 2022	SELL	$51.99 - $72.11 $462,503 - $641,490	-8,896 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$39.81 - $88.24 $3.35 Million - $7.43 Million	-84,242 Reduced 90.45%	8,896 $622,000
Q3 2021 Nov 12, 2021	BUY	$52.01 - $71.77 $1.79 Million - $2.47 Million	34,383 Added 58.52%	93,138 $4.86 Million
Q2 2021 Aug 12, 2021	BUY	$62.14 - $81.82 $285,160 - $375,471	4,589 Added 8.47%	58,755 $4 Million
Q1 2021 May 13, 2021	BUY	$59.42 - $85.46 $1.12 Million - $1.62 Million	18,908 Added 53.63%	54,166 $4.17 Million
Q4 2020 Feb 09, 2021	SELL	$40.64 - $61.38 $30,927 - $46,710	-761 Reduced 2.11%	35,258 $2.12 Million
Q3 2020 Nov 06, 2020	SELL	$37.76 - $48.49 $524,108 - $673,041	-13,880 Reduced 27.82%	36,019 $1.55 Million
Q2 2020 Aug 12, 2020	SELL	$37.03 - $60.0 $406,663 - $658,920	-10,982 Reduced 18.04%	49,899 $2.07 Million
Q1 2020 May 11, 2020	SELL	$35.02 - $65.64 $100,612 - $188,583	-2,873 Reduced 4.51%	60,881 $2.63 Million
Q4 2019 Feb 13, 2020	BUY	$33.17 - $65.23 $174,573 - $343,305	5,263 Added 9.0%	63,754 $3.53 Million
Q3 2019 Nov 12, 2019	BUY	$34.72 - $51.3 $1.36 Million - $2.01 Million	39,225 Added 203.6%	58,491 $2.03 Million
Q2 2019 Aug 13, 2019	SELL	$27.2 - $41.2 $1.28 Million - $1.93 Million	-46,940 Reduced 70.9%	19,266 $776,000
Q1 2019 May 14, 2019	BUY	$19.86 - $32.9 $882,300 - $1.46 Million	44,426 Added 203.98%	66,206 $2.18 Million
Q4 2018 Feb 14, 2019	BUY	$15.03 - $25.38 $327,353 - $552,776	21,780 New	21,780 $453,000

Others Institutions Holding KRYS

# of Institutions

302

Shares Held

24.5M

Call Options Held

444K

Put Options Held

325K

View Full List

About Krystal Biotech, Inc.

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.93B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

More about KRYS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account